CARDIFF ONCOLOGY INC's ticker is CRDF and the CUSIP is 14147L108.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $63 | -8.7% | 45,000 | -4.3% | 0.04% | -6.8% |
| Q2 2023 | $69 | +19.0% | 47,000 | +34.3% | 0.04% | +15.8% |
| Q1 2023 | $58 | +41.5% | 35,000 | +19.0% | 0.04% | +35.7% |
| Q4 2022 | $41 | -99.9% | 29,408 | +16.2% | 0.03% | 0.0% |
| Q3 2022 | $39,000 | -25.0% | 25,300 | +6.3% | 0.03% | -15.2% |
| Q2 2022 | $52,000 | +10.6% | 23,800 | +25.3% | 0.03% | +32.0% |
| Q1 2022 | $47,000 | -54.8% | 19,000 | +9.8% | 0.02% | -57.6% |
| Q4 2021 | $104,000 | +15.6% | 17,300 | +28.1% | 0.06% | +9.3% |
| Q3 2021 | $90,000 | +125.0% | 13,500 | +125.0% | 0.05% | +125.0% |
| Q2 2021 | $40,000 | +233.3% | 6,000 | +361.5% | 0.02% | +242.9% |
| Q1 2021 | $12,000 | -20.0% | 1,300 | +54.8% | 0.01% | -30.0% |
| Q4 2020 | $15,000 | +7.1% | 840 | -16.0% | 0.01% | -9.1% |
| Q3 2020 | $14,000 | -63.2% | 1,000 | -86.8% | 0.01% | -63.3% |
| Q2 2020 | $38,000 | – | 7,562 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 2,522,083 | $16,797,000 | 13.61% |
| Octagon Capital Advisors LP | 982,753 | $6,545,000 | 1.61% |
| Altium Capital Management LP | 348,888 | $2,324,000 | 0.61% |
| ACT CAPITAL MANAGEMENT, LLC | 102,500 | $683,000 | 0.35% |
| Eventide Asset Management | 1,670,399 | $11,125,000 | 0.15% |
| Artal Group S.A. | 750,000 | $4,995,000 | 0.11% |
| Virtus ETF Advisers LLC | 25,770 | $172,000 | 0.08% |
| HighVista Strategies LLC | 15,501 | $103,000 | 0.07% |
| ELKHORN PARTNERS LIMITED PARTNERSHIP | 13,500 | $90,000 | 0.05% |
| SCHOLTZ & COMPANY, LLC | 16,625 | $111,000 | 0.04% |